-
Je něco špatně v tomto záznamu ?
Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy
K. Bendickova, F. Tidu, J. Fric,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2009
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-04-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Medline Complete (EBSCOhost)
od 2011-01-01
Health & Medicine (ProQuest)
od 2009-04-01
Wiley Free Content
od 2009 do 2023
Wiley-Blackwell Open Access Titles
od 2009 do 2023
ROAD: Directory of Open Access Scholarly Resources
od 2008
PubMed
28606994
DOI
10.15252/emmm.201707698
Knihovny.cz E-zdroje
- MeSH
- imunosupresiva terapeutické užití MeSH
- kalcineurin metabolismus MeSH
- leukocyty imunologie MeSH
- lidé MeSH
- signální transdukce * MeSH
- transkripční faktory NFATC metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Myeloid leucocytes mediate host protection against infection and critically regulate inflammatory responses in body tissues. Pattern recognition receptor signalling is crucial for myeloid cell responses to pathogens, but growing evidence suggests an equally potent role for Calcineurin-NFAT signalling in control of myeloid cell function. All major subsets of myeloid leucocytes employ Calcineurin-NFAT signalling during immune responses to pathogens and/or tissue damage, but the influence this pathway exerts on pathogen clearance and host susceptibility to infection is not fully understood. Recent data from experimental models indicate that Calcineurin-NFAT signalling is essential for infection control, and calcineurin inhibitors used in transplantation medicine (including cyclosporine A and tacrolimus) are now being tested for efficacy in a diverse range of inflammatory conditions and autoimmune pathologies. Efforts to repurpose calcineurin inhibitor drugs for new therapeutic applications may yield rapid improvements in clinical outcomes, but the potential impact of these compounds on myeloid cell function in treated patients is largely unknown. Here we discuss Calcineurin-NFAT control of myeloid leucocyte function in the context of recent therapeutic developments and ongoing clinical studies.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024948
- 003
- CZ-PrNML
- 005
- 20180712111037.0
- 007
- ta
- 008
- 180709s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.15252/emmm.201707698 $2 doi
- 035 __
- $a (PubMed)28606994
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bendickova, Kamila $u Center for Translational Medicine (CTM), International Clinical Research Center (ICRC), St. Anne's University Hospital Brno, Brno, Czech Republic.
- 245 10
- $a Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy / $c K. Bendickova, F. Tidu, J. Fric,
- 520 9_
- $a Myeloid leucocytes mediate host protection against infection and critically regulate inflammatory responses in body tissues. Pattern recognition receptor signalling is crucial for myeloid cell responses to pathogens, but growing evidence suggests an equally potent role for Calcineurin-NFAT signalling in control of myeloid cell function. All major subsets of myeloid leucocytes employ Calcineurin-NFAT signalling during immune responses to pathogens and/or tissue damage, but the influence this pathway exerts on pathogen clearance and host susceptibility to infection is not fully understood. Recent data from experimental models indicate that Calcineurin-NFAT signalling is essential for infection control, and calcineurin inhibitors used in transplantation medicine (including cyclosporine A and tacrolimus) are now being tested for efficacy in a diverse range of inflammatory conditions and autoimmune pathologies. Efforts to repurpose calcineurin inhibitor drugs for new therapeutic applications may yield rapid improvements in clinical outcomes, but the potential impact of these compounds on myeloid cell function in treated patients is largely unknown. Here we discuss Calcineurin-NFAT control of myeloid leucocyte function in the context of recent therapeutic developments and ongoing clinical studies.
- 650 _2
- $a kalcineurin $x metabolismus $7 D019703
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a leukocyty $x imunologie $7 D007962
- 650 _2
- $a transkripční faktory NFATC $x metabolismus $7 D050778
- 650 12
- $a signální transdukce $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Tidu, Federico $u Center for Translational Medicine (CTM), International Clinical Research Center (ICRC), St. Anne's University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Fric, Jan $u Center for Translational Medicine (CTM), International Clinical Research Center (ICRC), St. Anne's University Hospital Brno, Brno, Czech Republic jan.fric@fnusa.cz.
- 773 0_
- $w MED00189522 $t EMBO molecular medicine $x 1757-4684 $g Roč. 9, č. 8 (2017), s. 990-999
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28606994 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712111330 $b ABA008
- 999 __
- $a ok $b bmc $g 1317079 $s 1021869
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 9 $c 8 $d 990-999 $i 1757-4684 $m EMBO molecular medicine $n EMBO Mol Med $x MED00189522
- LZP __
- $a Pubmed-20180709